SELLAS Life Sciences Group Files Proxy Statement
Ticker: SLS · Form: DEFA14A · Filed: Jun 10, 2025 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | DEFA14A |
| Filed Date | Jun 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, sec-filing
TL;DR
SELLAS Life Sciences Group filed its proxy statement, shareholders vote soon.
AI Summary
SELLAS Life Sciences Group, Inc. filed a Definitive Proxy Statement (DEFA14A) on June 10, 2025. This filing is related to the company's proxy materials, likely concerning upcoming shareholder meetings and voting matters. The company, formerly known as Galena Biopharma, Inc. and RXi Pharmaceuticals Corp, is incorporated in Delaware and headquartered in New York.
Why It Matters
This filing is crucial for shareholders as it outlines important information regarding voting rights, board nominations, and other corporate governance matters that will be decided at upcoming shareholder meetings.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial information or strategic changes that would immediately impact the company's risk profile.
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- Galena Biopharma, Inc. (company) — Former company name
- RXi Pharmaceuticals Corp (company) — Former company name
- 20250610 (date) — Filing date
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, or Definitive Proxy Statement, is used by companies to solicit proxy votes from shareholders for an upcoming meeting, providing details on matters to be voted upon.
When was this Definitive Proxy Statement filed?
This Definitive Proxy Statement was filed on June 10, 2025.
What are some former names of SELLAS Life Sciences Group, Inc.?
SELLAS Life Sciences Group, Inc. was formerly known as Galena Biopharma, Inc. and RXi Pharmaceuticals Corp.
Where is SELLAS Life Sciences Group, Inc. headquartered?
SELLAS Life Sciences Group, Inc. is headquartered at 7 Times Square, Suite 2503, New York, NY 10036.
What is the Standard Industrial Classification code for SELLAS Life Sciences Group, Inc.?
The Standard Industrial Classification code for SELLAS Life Sciences Group, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 10, 2025 regarding SELLAS Life Sciences Group, Inc. (SLS).